Positron Emission Tomography (PET) Imaging of Chemotherapy-Induced Cardiotoxicity
NCT07838649 is a phase 1 interventional trial sponsored by Washington University School of Medicine. As of 21 Nov 2026, it is not yet recruiting. It studies Fluorodeoxyglucose F18 and 68Ga-Galmydar in Breast Cancer, Cancer of the Breast and 3 more conditions. The registry lists an enrollment of 36 participants at 1 site in 1 country. The registry lists a start date of 1 Nov 2026 and a primary completion date of 12 Dec 2029. One of its registered investigators has a FindMyKOL profile.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT07838649 |
| Status | Not yet recruiting |
| Phase | Phase 1 |
| Study type | Interventional trial |
| Lead sponsor | Washington University School of Medicine |
| Enrollment | 36 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | Breast Cancer, Cancer of the Breast, Hodgkin Lymphoma, Lymphoma Cancer and Non-Hodgkin Lymphoma |
| Drugs | Fluorodeoxyglucose F18 and 68Ga-Galmydar |
| Start | 1 Nov 2026 |
| Primary completion | 12 Dec 2029 |
| Study completion | 12 Dec 2029 |
| Last update posted | 24 Sept 2026 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Pamela K Woodard, MD
Washington University School of Medicine
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Washington University School of Medicine
St Louis
Cynthia Ma, MD, PhDJie Zheng, PhDJoshua D Mitchell, MDKatherine N Weilbaecher, MDNeha Mehta-Shah, MDPamela K Woodard, MDRichard Laforest, PhDThomas H Schindler, MDVijay Sharma, PhDYan Yan, MD
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT07838649
Each answer restates registry values shown on this page.
What is NCT07838649?
NCT07838649 is a phase 1 interventional trial sponsored by Washington University School of Medicine. It studies Fluorodeoxyglucose F18 and 68Ga-Galmydar in Breast Cancer, Cancer of the Breast and 3 more conditions.
Is NCT07838649 recruiting?
As of 21 Nov 2026, it is not yet recruiting.
Who leads NCT07838649?
The registry names Pamela K Woodard, MD (principal investigator, Washington University School of Medicine) as the overall official.
Where does NCT07838649 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT07838649 study?
The registered drug and biological interventions are Fluorodeoxyglucose F18 and 68Ga-Galmydar.
When is NCT07838649 expected to complete?
The registry lists a primary completion date of 12 Dec 2029 and a study completion date of 12 Dec 2029. The sponsor last updated the record on 24 Sept 2026.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.